Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Icahn School of Medicine at Mount Sinai, New York

National Institutes of Health, Clinical Center, Bethesda

Winship Cancer Institute Emory University, Atlanta

Miami Cancer Institute, Miami

University Hospitals Seidman Cancer Center, Cleveland

University of Michigan Health, Ann Arbor

Karmanos Cancer Institute, Detroit

Masonic Cancer Center, University of Minnesota, Minneapolis

Washington University School of Medicine Siteman Cancer Center, St Louis

The University of Kansas Cancer Center, Fairway

University of Utah Huntsman Cancer Institute, Salt Lake City

University of California San Diego Moores Cancer Center, La Jolla

Stanford Cancer Institute, Stanford

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack